Expert Answer
Quick Answer
Experts are split. Attia uses it clinically for LDL. Huberman personally avoids it — insufficient human data. Hyman views it as a useful AMPK activator. Biggest risk: potent blood sugar lowering can cause hypoglycemia.
Moderate Consensus
on Berberine overall
Uses for LDL management via PCSK9 inhibition. Prefers metformin for glucose. Recommends Thorne brand.
Personally avoids berberine, metformin, and rapamycin — insufficient human data for longevity.
Positive as AMPK activator and herbal antimicrobial for gut health.
Berberine safety depends on use case. Attia uses it clinically as a weak PCSK9 inhibitor for LDL management, preferring Thorne brand. He calls it a "weak AMPK activator" and prefers pharmaceutical metformin for glucose control.
Huberman explicitly avoids berberine for longevity, citing insufficient human data and hypoglycemia risk. Hyman views it positively for AMPK activation and as an antimicrobial for gut dysbiosis.
Key risks: potent blood sugar lowering (hypoglycemia), GI side effects, CYP3A4/CYP2D6 drug interactions, and no pregnancy use. Long-term safety data is limited.
Attia considers it a weak AMPK activator similar to metformin but prefers pharmaceutical-grade metformin for glucose management due to better consistency.
This page covers what researchers agree on. Pro gives you the specific dosages, timing schedules, and interaction warnings they each recommend — with video citations you can verify.
Cancel anytime
Full Berberine Consensus Report
See what all 5 experts agree and disagree on